Funding from European and Developing Countries Clinical Trials Partnership (EDCTP) will allow testing of a novel whole-cell inactivated oral vaccine in clinical trials in Europe and Africa.
Vaxeal is a biopharmaceutical company developing therapeutic cancer vaccines and treatments for infectious diseases. It has several vaccine candidates in pre-clinical development targeting cancers and hepatitis C that are expected to begin clinical trials in Europe in 2014-2015. Vaxeal takes promising early-stage research from academic partners and advances it through clinical proof-of-concept, with the goal of improving patient access to new treatments.
Fao lessons learned from HPAI outbreaks in Asia 2005 - 2011Harm Kiezebrink
FAO has published a report on lessons learned from from the fight against highly pathogenic avian influenza in Asia between 2005 and 2011.
Since the emergence of H5N1 HPAI in 2003, the disease situation has evolved considerably. At the peak of avian influenza (AI) outbreaks in 2006, 63 countries in Asia, Europe and Africa were affected by the disease; it has now been eliminated from most of these countries. H5N1 is currently entrenched in a number of countries in Asia and the disease is endemic in China, Viet Nam, Indonesia, Bangladesh and large parts of eastern India. A number of countries in Asia, including the Lao People’s Democratic Republic (Lao PDR),Cambodia, Myanmar and Nepal, also experience regular outbreaks.
The period 2004 to 2008 saw a steady decline in disease outbreaks in poultry. While there has been an apparent increase in outbreak numbers since 2009, the 2011/2012 HPAI season saw a significant decline in poultry outbreaks. The last newly-infected country was Bhutan; this outbreak took place in February 2010. However, the disease is known to be under-reported and there is increasing evidence that H5N1 HPAI has become endemic in some of the smaller countries in Asia that have relatively undeveloped poultry industries; such countries include Cambodia and Nepal. It is estimated that the disease has resulted in the loss of over 400 million domestic poultry and has caused economic losses of over US$20 billion.
The information, generated from isolation and genetic and antigenic characterization of a large number of viruses in Asia and other parts of the world, coupled with the information on disease outbreaks, has improved our understanding of the virus’s evolution and the implications for its spread, infectivity and suitability for use in the development of vaccines. The current trends in evolution present a number of concerns, which include the emergence of second-, third- and fourth-order clades, demonstrating rapid evolution and rapid replacement of virus strains in some endemic regions, and the emergence of antigenic diversity, including changes in receptor binding capacity and the ability to break through existing vaccine strains.
Hydroxichloroquine and azitromycin as a treatment of covid 19gisa_legal
This document summarizes the results of a clinical trial that evaluated the effectiveness of hydroxychloroquine in treating COVID-19. Twenty patients received hydroxychloroquine and 16 patients did not receive treatment and served as controls. The primary outcome was viral clearance at day six, as measured by PCR testing of nasopharyngeal swabs. Patients receiving hydroxychloroquine showed a significantly higher rate of viral clearance at day six compared to controls. The addition of azithromycin to hydroxychloroquine treatment resulted in a higher rate of viral clearance than hydroxychloroquine alone.
threat to malaria control. Resistance to rifampicin, a
The threat of antimicrobial resistance is growing due to both appropriate and inappropriate use of antibiotics in humans and animals. Many infections are becoming difficult or impossible to treat as bacteria evolve resistance. While strategies have been implemented, more action is needed worldwide to curb resistance and preserve the effectiveness of existing drugs. This book examines experiences addressing resistance in different areas and progress since 2001, highlighting the need for continued efforts, especially political commitment, to combat the threat.
Antibiotic resistance is one of the biggest threats facing us today!
European Antibiotic Awareness Day (EAAD) is part of the UK 5 Year Antimicrobial Resistance Strategy 2013 to 2018, which focuses on antibiotics and sets out actions to slow the development and spread of antimicrobial resistance.
This year, to run in line with EAAD; Public Health England has established the Antibiotic Guardian pledge campaign. It calls on everyone in the UK, the public and healthcare community to become antibiotics guardian by choosing one simple pledge about how they will make better use of these vital medicines.
To ensure that the information and knowledge on Antibiotic Stewardship is disseminated to those practising healthcare across the nation, a series of awareness and educational events have been developed. These educational workshop events, to be held in Leeds, Birmingham and London, will provide guidance, resources and information for practitioners on topics associated with antibiotic awareness. The events will provide an opportunity to understand how you and your organisation can support combat the global challenge faced by antibiotic resistance whilst gaining advice, support and resources to inform patients and staff.
This document summarizes a workshop on tackling antimicrobial resistance held in Bristol, England. The workshop covered national actions and strategies to address AMR, including the UK's 5-year AMR strategy with 7 key areas of action. It discussed improved surveillance of antibiotic use and resistance in England, as well as initiatives to optimize antibiotic prescribing and antimicrobial stewardship. The workshop emphasized the role of all stakeholders in addressing AMR and highlighted ongoing work in the South West of England to tackle AMR through various programs and collaborations.
The document discusses the role of diagnostics in preventing antimicrobial resistance (AMR). It notes that inappropriate antibiotic use is fueling the emergence of AMR globally and reducing treatment options. Currently 700,000 deaths per year are due to drug-resistant infections and this could rise to 10 million by 2050. Diagnostics can play a key role in optimizing antibiotic use, preserving new drugs, and enabling surveillance. The document outlines FIND's strategy to develop and promote rapid diagnostic tests to improve rational antibiotic use in low-resource settings and preserve antibiotics by enabling more targeted treatment.
Vaxeal is a biopharmaceutical company developing therapeutic cancer vaccines and treatments for infectious diseases. It has several vaccine candidates in pre-clinical development targeting cancers and hepatitis C that are expected to begin clinical trials in Europe in 2014-2015. Vaxeal takes promising early-stage research from academic partners and advances it through clinical proof-of-concept, with the goal of improving patient access to new treatments.
Fao lessons learned from HPAI outbreaks in Asia 2005 - 2011Harm Kiezebrink
FAO has published a report on lessons learned from from the fight against highly pathogenic avian influenza in Asia between 2005 and 2011.
Since the emergence of H5N1 HPAI in 2003, the disease situation has evolved considerably. At the peak of avian influenza (AI) outbreaks in 2006, 63 countries in Asia, Europe and Africa were affected by the disease; it has now been eliminated from most of these countries. H5N1 is currently entrenched in a number of countries in Asia and the disease is endemic in China, Viet Nam, Indonesia, Bangladesh and large parts of eastern India. A number of countries in Asia, including the Lao People’s Democratic Republic (Lao PDR),Cambodia, Myanmar and Nepal, also experience regular outbreaks.
The period 2004 to 2008 saw a steady decline in disease outbreaks in poultry. While there has been an apparent increase in outbreak numbers since 2009, the 2011/2012 HPAI season saw a significant decline in poultry outbreaks. The last newly-infected country was Bhutan; this outbreak took place in February 2010. However, the disease is known to be under-reported and there is increasing evidence that H5N1 HPAI has become endemic in some of the smaller countries in Asia that have relatively undeveloped poultry industries; such countries include Cambodia and Nepal. It is estimated that the disease has resulted in the loss of over 400 million domestic poultry and has caused economic losses of over US$20 billion.
The information, generated from isolation and genetic and antigenic characterization of a large number of viruses in Asia and other parts of the world, coupled with the information on disease outbreaks, has improved our understanding of the virus’s evolution and the implications for its spread, infectivity and suitability for use in the development of vaccines. The current trends in evolution present a number of concerns, which include the emergence of second-, third- and fourth-order clades, demonstrating rapid evolution and rapid replacement of virus strains in some endemic regions, and the emergence of antigenic diversity, including changes in receptor binding capacity and the ability to break through existing vaccine strains.
Hydroxichloroquine and azitromycin as a treatment of covid 19gisa_legal
This document summarizes the results of a clinical trial that evaluated the effectiveness of hydroxychloroquine in treating COVID-19. Twenty patients received hydroxychloroquine and 16 patients did not receive treatment and served as controls. The primary outcome was viral clearance at day six, as measured by PCR testing of nasopharyngeal swabs. Patients receiving hydroxychloroquine showed a significantly higher rate of viral clearance at day six compared to controls. The addition of azithromycin to hydroxychloroquine treatment resulted in a higher rate of viral clearance than hydroxychloroquine alone.
threat to malaria control. Resistance to rifampicin, a
The threat of antimicrobial resistance is growing due to both appropriate and inappropriate use of antibiotics in humans and animals. Many infections are becoming difficult or impossible to treat as bacteria evolve resistance. While strategies have been implemented, more action is needed worldwide to curb resistance and preserve the effectiveness of existing drugs. This book examines experiences addressing resistance in different areas and progress since 2001, highlighting the need for continued efforts, especially political commitment, to combat the threat.
Antibiotic resistance is one of the biggest threats facing us today!
European Antibiotic Awareness Day (EAAD) is part of the UK 5 Year Antimicrobial Resistance Strategy 2013 to 2018, which focuses on antibiotics and sets out actions to slow the development and spread of antimicrobial resistance.
This year, to run in line with EAAD; Public Health England has established the Antibiotic Guardian pledge campaign. It calls on everyone in the UK, the public and healthcare community to become antibiotics guardian by choosing one simple pledge about how they will make better use of these vital medicines.
To ensure that the information and knowledge on Antibiotic Stewardship is disseminated to those practising healthcare across the nation, a series of awareness and educational events have been developed. These educational workshop events, to be held in Leeds, Birmingham and London, will provide guidance, resources and information for practitioners on topics associated with antibiotic awareness. The events will provide an opportunity to understand how you and your organisation can support combat the global challenge faced by antibiotic resistance whilst gaining advice, support and resources to inform patients and staff.
This document summarizes a workshop on tackling antimicrobial resistance held in Bristol, England. The workshop covered national actions and strategies to address AMR, including the UK's 5-year AMR strategy with 7 key areas of action. It discussed improved surveillance of antibiotic use and resistance in England, as well as initiatives to optimize antibiotic prescribing and antimicrobial stewardship. The workshop emphasized the role of all stakeholders in addressing AMR and highlighted ongoing work in the South West of England to tackle AMR through various programs and collaborations.
The document discusses the role of diagnostics in preventing antimicrobial resistance (AMR). It notes that inappropriate antibiotic use is fueling the emergence of AMR globally and reducing treatment options. Currently 700,000 deaths per year are due to drug-resistant infections and this could rise to 10 million by 2050. Diagnostics can play a key role in optimizing antibiotic use, preserving new drugs, and enabling surveillance. The document outlines FIND's strategy to develop and promote rapid diagnostic tests to improve rational antibiotic use in low-resource settings and preserve antibiotics by enabling more targeted treatment.
Antibiotic Guardian Leeds Workshop 20164 All of Us
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
Antibiotic Guardian London Workshop 20164 All of Us
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
The Detection and Identification of Infectious Agents Innovation Platform aims to encourage the development, uptake and adoption of clinically useful and commercially viable diagnostics for detecting infectious agents in humans and animals. The Technology Strategy Board launched the platform in 2008 and will invest up to £50 million over five years, together with additional funding from government departments like the Department of Health. More rapid and accurate diagnosis of infectious diseases can lead to targeted treatments that reduce the social and economic impact of diseases and create opportunities for UK industry.
This newsletter provides information on global immunization activities and events. It discusses World Immunization Week from 21-28 April 2012, with the theme of "Protect your world, get vaccinated". Countries will raise awareness of how immunization saves lives and increase vaccination coverage. It also provides updates on immunization programs and initiatives in several WHO regions, including preparations for the second African Immunization Week and third Vaccination Week in the Eastern Mediterranean. Technical information is given on projects and guidelines related to vaccine safety, monitoring, and developing country needs.
Global response to antimicrobial resistance, WHO, OIE, CDC summry. Jan NkeckJ-réné Nkeck
The document summarizes the global response to antimicrobial resistance by the World Health Organization (WHO), World Organization for Animal Health (OIE), and Centers for Disease Control and Prevention (CDC). The WHO endorsed a global action plan with five strategic objectives including improving awareness, strengthening surveillance, reducing infection, optimizing antimicrobial use, and increasing investment. The OIE and CDC also outlined strategies focusing on awareness, surveillance, infection prevention, optimizing use, and research. The take home message is that antimicrobial resistance is a serious global problem requiring a coordinated multi-sectoral response, with low-income countries being most vulnerable.
The document outlines plans for developing a global roadmap to defeat meningitis by 2030. It discusses:
1) Consultations held with over 100 stakeholders to finalize the strategy and prioritize prevention, surveillance, diagnosis and treatment.
2) Next steps including establishing partnerships, developing monitoring plans, and submitting a resolution to the World Health Assembly in May 2020.
3) The roadmap will provide a framework for implementing a global strategy through regional plans to control bacterial meningitis and work towards eliminating epidemics by 2030.
The National University of Singapore (NUS) is partnering with the Foundation for Innovative New Diagnostics (FIND) to develop a novel point-of-care diagnostic test for tuberculosis (TB) detection. NUS researchers have identified specific mycolic acid biomarkers in sputum samples that can distinguish active TB infections from non-infections or cured cases. NUS will work to develop antibodies to these biomarkers for use in an immunoassay-based diagnostic test, while FIND will provide expertise to develop the test into a product. The goal is to make TB diagnosis more affordable, easy-to-use, and accurate for use in resource-limited settings.
Antimicrobial Resistance A One Health Challenge for Joint Action Ekaterina Bessonova
1. Antimicrobial resistance is a major global public health threat that requires a One Health approach and joint action across human, animal, and environmental sectors.
2. Key international organizations like FAO, OIE, and WHO have been collaborating for over 20 years to address antimicrobial resistance through activities like establishing guidelines, supporting country capacity building, and developing global and national action plans.
3. National action plans should focus on improving awareness and surveillance systems, optimizing antimicrobial use, and conducting research to address knowledge gaps, with a goal of ensuring sustainable and coordinated responses to antimicrobial resistance as a shared challenge.
Survey to Assess the Attitude of Nursing Students Regarding Prevention of COV...YogeshIJTSRD
The present study has been conducted to know the attitude of nursing students regarding preventive techniques to prevent from COVID 19 during COVID 19 pandemic. In order to achieve the objectives non experimental approach with survey research design was adopted. Setting of the study selected was Dr. Achal Singh Yadav institute of nursing and paramedical sciences, Lucknow. The selection of sample was done by using convenient non probability sampling technique. The sample size was 30. The method of data collection was using demographic variables questions and structured attitude rating scale related to attitude regarding prevention of COVID 19. Result shown that nursing students had neutral attitude regarding prevention of COVID 19 and there is no significant association between demographic variables with attitude of nursing students, hence hypothesis 1 rejected. Saniya Susan Issac | Sarita Bhatt | Bince Varghese "Survey to Assess the Attitude of Nursing Students Regarding Prevention of COVID-19 during COVID19 Pandemic" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd41258.pdf Paper URL: https://www.ijtsrd.commedicine/nursing/41258/survey-to-assess-the-attitude-of-nursing-students-regarding-prevention-of-covid19-during-covid19-pandemic/saniya-susan-issac
Impact of Covid19 Knowledge, Attitude and Practice KAP in Food Industry, Indiaijtsrd
COVID 19 coronavirus is one of the highly infectious and transmittable disease caused by SARS COV 2 that human era has ever faced. At the end of December 2019, novel virus named COVID 19 emerged in large seafood market at Wuhan china, causing respiratory infections thereby death cases is numerically increasing in lakh due to rapid transmission of virus. Background Global covid 19 pandemic generate a pressing need to upgrade food establishments with standard Food safety protocols which are required to keep their premises safe for their guests and customers. Objectives The objective of the study is to assess the knowledge, awareness and practice among food handlers. Methodology A voluntary online survey was conducted among food handlers working in different food outlets and star hotels in TamilNadu, India. A questionnaire was structured and mailed to the participants. Results A total of 53 responses have been recorded. In which ninety seven percentage respondents are male and three percentage of respondents are female. Ninety three percent of the respondents are aware that hand dryers are not effective in killing coronavirus. Eighty five percent of respondents strongly agreed to the statement of educating patients, household members and caregivers about covid 19. Conclusion The results of this study show that, majority of the food handlers has excellent knowledge, hygienic practice and awareness of covid 19. Ms. J. Suja Kannu | Ms. J. Vinodha Evangeline | K. Karthick "Impact of Covid19: Knowledge, Attitude and Practice (KAP) in Food Industry, India" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-4 , June 2020, URL: https://www.ijtsrd.com/papers/ijtsrd31649.pdf Paper Url :https://www.ijtsrd.com/home-science/health-and-hygiene/31649/impact-of-covid19-knowledge-attitude-and-practice-kap-in-food-industry-india/ms-j-suja-kannu
This document discusses the development and introduction of dengue vaccines. It notes that while vaccines may be available starting in 2015, public sectors have historically been poor at introducing new technologies, particularly in low-income countries. The document proposes a framework to help accelerate dengue vaccine introduction. Key elements of the framework include regulatory cooperation across countries, forecasting models to help countries plan introduction strategies, preparing documents for WHO review, conducting cost analyses, and coordinating global decision making. The goal is to help ensure dengue vaccines have a more rapid impact through a clear and workable introduction strategy.
Antimicrobial resistance (AMR) poses a major threat to global healthcare. If left unchecked, more deaths will occur from resistant infections than cancer by 2050. Local actions are needed to tackle AMR through appropriate antimicrobial use. The document discusses various tools and strategies available for local antimicrobial stewardship groups, healthcare professionals, and the public to raise awareness and promote prudent antibiotic use. Public awareness campaigns like the European Antibiotic Awareness Day (EAAD) educate about only taking antibiotics when necessary. Local examples show how engaging stakeholders and monitoring antibiotic prescribing can reduce unnecessary use. Coordinated global and local efforts are required to slow the development of AMR.
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDCDRIVE research
This document summarizes ECDC's work on influenza vaccine effectiveness studies in Europe. It outlines ECDC's strategic objectives related to influenza, which include improving surveillance information, promoting vaccination, and strengthening pandemic preparedness. The document discusses ECDC's priorities for 2019, which focus on transforming influenza surveillance, monitoring vaccination programs, and pandemic preparedness. It provides details on ECDC's influenza outputs and activities for 2019, including surveillance reports, vaccine effectiveness studies, and preparedness assessments.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
These slides offer a useful, referenced resource for members and visitors to our website who wish to share the story about the value of medicines. They complement existing resources available on the ABPI website and will be updated regularly as the ABPI updates other data and content.
Presentation by the Director-elect, Dr Andrea Ammon, for her hearing at the Environment, Public Health and Food Safety Committee of the European Parliament
This document discusses the problem of increasing antimicrobial resistance and outlines strategies for antimicrobial stewardship programs. It recognizes antimicrobial resistance as a serious global problem that requires immediate action. Antimicrobial stewardship is defined as optimizing antibiotic use through selecting appropriate treatment duration, dose, and spectrum of coverage. The document recommends establishing multidisciplinary stewardship teams and implementing interventions like guidelines, audit and feedback, and streamlining of therapy to improve antibiotic use and slow the development of resistance. Physicians are identified as key players that can help address the problem through their antibiotic prescribing practices.
Lucia PASTORE CELENTANO, MD, MSc
Head of the Vaccine Preventable Diseases Programme, ECDC
“Addressing vaccine hesitancy in challenging times”
European Health Forum Gastein, 05 October 2017
Fact sheet presenting the life sciences industry in the Quebec City region. Produced by Quebec International. http://quebecinternational.ca/key-industries/
The study found that a recent HIV vaccine trial that used the HIV envelope as an immunogen was unsuccessful at protecting against HIV infection. The vaccine selectively recruited antibodies that reacted with both the HIV envelope and common intestinal microbes. This finding suggests that the vaccine induced the same diverted, ineffective antibody response that occurs during acute HIV infection. The results raise the hypothesis that the intestinal microbiome imprinted the immune system to make these cross-reactive antibodies, and that improving the antibody response may require blocking undesired HIV sites during vaccination or vaccinating earlier in life.
MVI's mission is to accelerate malaria vaccine development and ensure availability in developing countries. Its goal is an 80% effective vaccine lasting 4+ years by 2025. Malaria infects 250 million people annually and kills 900,000, mostly children in Africa. Vaccine development faces challenges due to the parasite's complexity and limited commercial markets. MVI partners with organizations to systematically develop promising approaches through clinical trials. Its current strategy focuses on pre-erythrocytic, transmission-blocking, and P. vivax vaccines. With a phase 3 trial underway, MVI's public-private model brings malaria vaccines closer to reality.
Antibiotic Guardian Leeds Workshop 20164 All of Us
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
Antibiotic Guardian London Workshop 20164 All of Us
Antibiotic resistance is one of the biggest threats facing us today.
Why it is relevant to you: without effective antibiotics many routine treatments will become increasingly dangerous. Setting broken bones, basic operations, even chemotherapy and animal health all rely on access to antibiotics that work.
What we want you to do: To slow resistance we need to cut the unnecessary use of antibiotics. We invite the public, students and educators, farmers, the veterinary and medical communities and professional organisations, to become Antibiotic Guardians.
Call to action: Choose one simple pledge about how you’ll make better use of antibiotics and help save these vital medicines from becoming obsolete.
The Detection and Identification of Infectious Agents Innovation Platform aims to encourage the development, uptake and adoption of clinically useful and commercially viable diagnostics for detecting infectious agents in humans and animals. The Technology Strategy Board launched the platform in 2008 and will invest up to £50 million over five years, together with additional funding from government departments like the Department of Health. More rapid and accurate diagnosis of infectious diseases can lead to targeted treatments that reduce the social and economic impact of diseases and create opportunities for UK industry.
This newsletter provides information on global immunization activities and events. It discusses World Immunization Week from 21-28 April 2012, with the theme of "Protect your world, get vaccinated". Countries will raise awareness of how immunization saves lives and increase vaccination coverage. It also provides updates on immunization programs and initiatives in several WHO regions, including preparations for the second African Immunization Week and third Vaccination Week in the Eastern Mediterranean. Technical information is given on projects and guidelines related to vaccine safety, monitoring, and developing country needs.
Global response to antimicrobial resistance, WHO, OIE, CDC summry. Jan NkeckJ-réné Nkeck
The document summarizes the global response to antimicrobial resistance by the World Health Organization (WHO), World Organization for Animal Health (OIE), and Centers for Disease Control and Prevention (CDC). The WHO endorsed a global action plan with five strategic objectives including improving awareness, strengthening surveillance, reducing infection, optimizing antimicrobial use, and increasing investment. The OIE and CDC also outlined strategies focusing on awareness, surveillance, infection prevention, optimizing use, and research. The take home message is that antimicrobial resistance is a serious global problem requiring a coordinated multi-sectoral response, with low-income countries being most vulnerable.
The document outlines plans for developing a global roadmap to defeat meningitis by 2030. It discusses:
1) Consultations held with over 100 stakeholders to finalize the strategy and prioritize prevention, surveillance, diagnosis and treatment.
2) Next steps including establishing partnerships, developing monitoring plans, and submitting a resolution to the World Health Assembly in May 2020.
3) The roadmap will provide a framework for implementing a global strategy through regional plans to control bacterial meningitis and work towards eliminating epidemics by 2030.
The National University of Singapore (NUS) is partnering with the Foundation for Innovative New Diagnostics (FIND) to develop a novel point-of-care diagnostic test for tuberculosis (TB) detection. NUS researchers have identified specific mycolic acid biomarkers in sputum samples that can distinguish active TB infections from non-infections or cured cases. NUS will work to develop antibodies to these biomarkers for use in an immunoassay-based diagnostic test, while FIND will provide expertise to develop the test into a product. The goal is to make TB diagnosis more affordable, easy-to-use, and accurate for use in resource-limited settings.
Antimicrobial Resistance A One Health Challenge for Joint Action Ekaterina Bessonova
1. Antimicrobial resistance is a major global public health threat that requires a One Health approach and joint action across human, animal, and environmental sectors.
2. Key international organizations like FAO, OIE, and WHO have been collaborating for over 20 years to address antimicrobial resistance through activities like establishing guidelines, supporting country capacity building, and developing global and national action plans.
3. National action plans should focus on improving awareness and surveillance systems, optimizing antimicrobial use, and conducting research to address knowledge gaps, with a goal of ensuring sustainable and coordinated responses to antimicrobial resistance as a shared challenge.
Survey to Assess the Attitude of Nursing Students Regarding Prevention of COV...YogeshIJTSRD
The present study has been conducted to know the attitude of nursing students regarding preventive techniques to prevent from COVID 19 during COVID 19 pandemic. In order to achieve the objectives non experimental approach with survey research design was adopted. Setting of the study selected was Dr. Achal Singh Yadav institute of nursing and paramedical sciences, Lucknow. The selection of sample was done by using convenient non probability sampling technique. The sample size was 30. The method of data collection was using demographic variables questions and structured attitude rating scale related to attitude regarding prevention of COVID 19. Result shown that nursing students had neutral attitude regarding prevention of COVID 19 and there is no significant association between demographic variables with attitude of nursing students, hence hypothesis 1 rejected. Saniya Susan Issac | Sarita Bhatt | Bince Varghese "Survey to Assess the Attitude of Nursing Students Regarding Prevention of COVID-19 during COVID19 Pandemic" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-5 | Issue-4 , June 2021, URL: https://www.ijtsrd.compapers/ijtsrd41258.pdf Paper URL: https://www.ijtsrd.commedicine/nursing/41258/survey-to-assess-the-attitude-of-nursing-students-regarding-prevention-of-covid19-during-covid19-pandemic/saniya-susan-issac
Impact of Covid19 Knowledge, Attitude and Practice KAP in Food Industry, Indiaijtsrd
COVID 19 coronavirus is one of the highly infectious and transmittable disease caused by SARS COV 2 that human era has ever faced. At the end of December 2019, novel virus named COVID 19 emerged in large seafood market at Wuhan china, causing respiratory infections thereby death cases is numerically increasing in lakh due to rapid transmission of virus. Background Global covid 19 pandemic generate a pressing need to upgrade food establishments with standard Food safety protocols which are required to keep their premises safe for their guests and customers. Objectives The objective of the study is to assess the knowledge, awareness and practice among food handlers. Methodology A voluntary online survey was conducted among food handlers working in different food outlets and star hotels in TamilNadu, India. A questionnaire was structured and mailed to the participants. Results A total of 53 responses have been recorded. In which ninety seven percentage respondents are male and three percentage of respondents are female. Ninety three percent of the respondents are aware that hand dryers are not effective in killing coronavirus. Eighty five percent of respondents strongly agreed to the statement of educating patients, household members and caregivers about covid 19. Conclusion The results of this study show that, majority of the food handlers has excellent knowledge, hygienic practice and awareness of covid 19. Ms. J. Suja Kannu | Ms. J. Vinodha Evangeline | K. Karthick "Impact of Covid19: Knowledge, Attitude and Practice (KAP) in Food Industry, India" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-4 , June 2020, URL: https://www.ijtsrd.com/papers/ijtsrd31649.pdf Paper Url :https://www.ijtsrd.com/home-science/health-and-hygiene/31649/impact-of-covid19-knowledge-attitude-and-practice-kap-in-food-industry-india/ms-j-suja-kannu
This document discusses the development and introduction of dengue vaccines. It notes that while vaccines may be available starting in 2015, public sectors have historically been poor at introducing new technologies, particularly in low-income countries. The document proposes a framework to help accelerate dengue vaccine introduction. Key elements of the framework include regulatory cooperation across countries, forecasting models to help countries plan introduction strategies, preparing documents for WHO review, conducting cost analyses, and coordinating global decision making. The goal is to help ensure dengue vaccines have a more rapid impact through a clear and workable introduction strategy.
Antimicrobial resistance (AMR) poses a major threat to global healthcare. If left unchecked, more deaths will occur from resistant infections than cancer by 2050. Local actions are needed to tackle AMR through appropriate antimicrobial use. The document discusses various tools and strategies available for local antimicrobial stewardship groups, healthcare professionals, and the public to raise awareness and promote prudent antibiotic use. Public awareness campaigns like the European Antibiotic Awareness Day (EAAD) educate about only taking antibiotics when necessary. Local examples show how engaging stakeholders and monitoring antibiotic prescribing can reduce unnecessary use. Coordinated global and local efforts are required to slow the development of AMR.
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDCDRIVE research
This document summarizes ECDC's work on influenza vaccine effectiveness studies in Europe. It outlines ECDC's strategic objectives related to influenza, which include improving surveillance information, promoting vaccination, and strengthening pandemic preparedness. The document discusses ECDC's priorities for 2019, which focus on transforming influenza surveillance, monitoring vaccination programs, and pandemic preparedness. It provides details on ECDC's influenza outputs and activities for 2019, including surveillance reports, vaccine effectiveness studies, and preparedness assessments.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
These slides offer a useful, referenced resource for members and visitors to our website who wish to share the story about the value of medicines. They complement existing resources available on the ABPI website and will be updated regularly as the ABPI updates other data and content.
Presentation by the Director-elect, Dr Andrea Ammon, for her hearing at the Environment, Public Health and Food Safety Committee of the European Parliament
This document discusses the problem of increasing antimicrobial resistance and outlines strategies for antimicrobial stewardship programs. It recognizes antimicrobial resistance as a serious global problem that requires immediate action. Antimicrobial stewardship is defined as optimizing antibiotic use through selecting appropriate treatment duration, dose, and spectrum of coverage. The document recommends establishing multidisciplinary stewardship teams and implementing interventions like guidelines, audit and feedback, and streamlining of therapy to improve antibiotic use and slow the development of resistance. Physicians are identified as key players that can help address the problem through their antibiotic prescribing practices.
Lucia PASTORE CELENTANO, MD, MSc
Head of the Vaccine Preventable Diseases Programme, ECDC
“Addressing vaccine hesitancy in challenging times”
European Health Forum Gastein, 05 October 2017
Fact sheet presenting the life sciences industry in the Quebec City region. Produced by Quebec International. http://quebecinternational.ca/key-industries/
The study found that a recent HIV vaccine trial that used the HIV envelope as an immunogen was unsuccessful at protecting against HIV infection. The vaccine selectively recruited antibodies that reacted with both the HIV envelope and common intestinal microbes. This finding suggests that the vaccine induced the same diverted, ineffective antibody response that occurs during acute HIV infection. The results raise the hypothesis that the intestinal microbiome imprinted the immune system to make these cross-reactive antibodies, and that improving the antibody response may require blocking undesired HIV sites during vaccination or vaccinating earlier in life.
MVI's mission is to accelerate malaria vaccine development and ensure availability in developing countries. Its goal is an 80% effective vaccine lasting 4+ years by 2025. Malaria infects 250 million people annually and kills 900,000, mostly children in Africa. Vaccine development faces challenges due to the parasite's complexity and limited commercial markets. MVI partners with organizations to systematically develop promising approaches through clinical trials. Its current strategy focuses on pre-erythrocytic, transmission-blocking, and P. vivax vaccines. With a phase 3 trial underway, MVI's public-private model brings malaria vaccines closer to reality.
1- MarketingBefore putting the product into the market, the prod.docxmonicafrancis71118
1- Marketing
Before putting the product into the market, the product goes through several stages. One of the most important stages is to determine the price of the product. After that, it will be studied by asking questions to customers and anticipate their requirements in terms of shape, colour phrases recorded on it. It can be applied using servery or interview the customer. Finally, the product needs to be promoting before it is been released, so electronic, and visual and audio can be used as advertising. However, in this experiment, we will focus only on the total cost of the product and then work on finding who develops the product….[9] [10].
1.1 Estimating of the total price.
For the antibiotic spray, it can be estimate the total price depend on the type of the material which were be used. Thus, the material in the table estimates the total price.
Material
Discerption
Brand/ manufacture
Price Ink VAT.
[1] Cefuroxime(as Cefuroxime sodium) 1.5 gram.
CEFUROXIME is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections
£4.70
[2] Sterile Water (1000ml)
Single Bottle of Sterile Water (1000ml)
Baxter
£3.54
[3] 73.5 mg of sodium
Sodium Bicarbonate 2kg - Pharmaceutical Grade (Bicarb/Bicarbonate of Soda)
£6.49
[1] Metronidazole
Metronidazole 500mg/100ml infusion 100ml bags (A A H Pharmaceuticals Ltd)
£63.86
[4] Phosphatebuffer (pKa=7.2)
PBS405.1 Virtual PHOSPHATE BUFFERED SALINE pH 7.4 10X Liquid Concentrate, 1L
£22.75
[5] Brilliant Blue FCF
1 kilogram
£6-8
[6] 100ml Stainless Steel
Empty stainless bottle spray
£7-9
Total price
£118
2- Companies and industry
There are many companies interested to work on or collaborate for developing the antibiotic. Following, there are some of the companies, Charities and universities, which they work hardly to improve public health and more specifically in the development of antibiotics. Thus, the product will be a focuses for them and new idea that can be started to develop and prove its effectiveness. Then, it can be put in the market, which many people can take advantage of the ease and licences of the product.
2.1. GSK Company [13]
At GSK, they are at the forefront of researching new ways to tackle some of the world’s biggest healthcare challenges. So as antibiotic resistance grows, they are investing in new ways to fight infection.
Their approach is to make the most of their own expertise and experience, while at the same time forming complementary partnerships and alliances with others who bring different kinds of expertise. Their vision for the world, where everyone has access to the vaccines they need, depends on a steady supply of great ideas and brilliant science. They have much to offer and through collaboration, they can achieve so much more.
For example, more than 90% of the vaccines in their pipeline are being developed in partnership with others. They have a long track rec.
Africa CDC, FIND partner to build capacity for COVID-19 rapid diagnostic test...SABC News
The Foundation for Innovative New Diagnostics (FIND) and the Africa Centres for Disease Control and Prevention (Africa CDC) have announced a new partnership to build capacity in readiness for the introduction of new, high-quality antigen rapid diagnostic tests (RDTs) for COVID-19 that are anticipated to become available soon
Overview of the Decade of Vaccines Collaboration including background, structure and vision for creation of the Global Vaccines Action Plan.
www.dovcollaboration.org
Incidence of Neonatal Septicemia in Babies Admitted in Pediatric Ward of KIU...PUBLISHERJOURNAL
This research was done to determine factors that influence the occurrence of neonatal septicemia among babies admitted in Kampala international university teaching hospital. This study was guided by the following objectives: to assess the maternal related factors associated with occurrence of neonatal septicemia among babies admitted in Pediatric ward of Kampala international university teaching hospital; to determine neonatal related factors associated with occurrence of neonatal septicemia among babies admitted in Pediatric ward of Kampala international university teaching hospital and to determine the social-economic factors associated with occurrence of neonatal septicemia among babies admitted in Pediatric ward of Kampala international university teaching hospital. A cross sectional study design was used in this study; A sample of 134 respondents were studied which included neonates/caretakers and health workers; data was collected with the use of observation, interview guide and questionnaires; data analysis and interpretation were done using Statistical package for social sciences (SPSS) to generate descriptive statistics and Chi-square p-values that were used to draw conclusion of the study. The results from this research showed that; - the maternal factors that influenced the occurrence of neonatal septicemia among babies admitted in pediatric ward of Kampala international university teaching hospital were inadequate Antenatal Care (ANC) attendance, prolonged rupture of membrane, bathing neonates with herbal medicines and place of delivery whereby a significant number of mothers delivered from home. On the neonatal factors the researcher found out that birth weight had a significant influence on the occurrence of neonatal septicemia among babies admitted in pediatric ward of Kampala international university teaching hospital. Finally, the study identified the socio-economic factors responsible for the occurrence of neonatal septicemia among babies admitted in pediatric ward of Kampala international university teaching hospital as washing hands before handling the neonates, low level of monthly household income and low level of education among caretakers. Based on the findings of this study, the researcher recommends that the Government through the DHOs offices should embark on health education by educating the pregnant women on the dangers of giving birth from their homes and also being helped by unqualified midwives. Also, the government through district sensitization programs should encourage pregnant women to seek antenatal care at the health facilities where they can be health educated, comprehensively screened and treated of infections to prevent spread of infections to newborns.
Keywords: Pediatric, Septicemia, Pregnant Women, Health Education, Antenatal care.
________________________________________
Planting the orchard – an ILRI livestock vaccine initiative (ILVAC)ILRI
The goal of ILRI’s Vaccine Biosciences group is to build a hub of research excellence dedicated to developing vaccine-based solutions to reduce disease burdens that limit livestock productivity in smallholder and pastoral farming systems.
Immuno Cure secured HK$8 million in funding from HKSTP to conduct a phase 1 clinical trial of ICVAX, a therapeutic HIV vaccine. ICVAX was developed using Immuno Cure's patented PD-1-Enhanced DNA vaccine platform and aims to induce viral-specific T cells to achieve functional cure of HIV. The clinical trial will evaluate the safety and immunogenicity of ICVAX in stable HIV patients in China and take 18-24 months to complete. Immuno Cure previously received HK$8.4 million from the ITF and is collaborating with HKU AIDS Institute, who received HK$47 million for HIV research.
KCR features in the newest Pharma Voice, June 2017, top industry publication. Andrzej Piotrowski, MD, Ph.D., Medical Monitor at KCR, commented on malaria treatment and research.
LEVERAGING PRIVATE-PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSEiQHub
The document discusses leveraging private-public partnerships (PPPs) in COVID-19 pandemic response. It provides context on global vaccine trends pre-COVID, then discusses the major impacts of the pandemic on clinical development, trials, and manufacturing. It highlights the roles of developing country vaccine manufacturers and IVI in responding through PPPs. IVI in particular has built partnerships across regions and leveraged over $30 million to develop affordable vaccines for cholera, typhoid and other diseases.
The document discusses GVN's response to the 2014-2015 Ebola outbreak in West Africa. Specifically, it summarizes that GVN has taken a leadership role by providing authoritative information on Ebola to the public and experts, sharing expert opinions on vaccine and treatment development, advocating for more funding for medical virology research, and working to support Ebola researchers through funding and facilitating collaborations. It also lists several GVN researchers who are working on understanding and developing treatments for Ebola virus.
Pherecydes Pharma has launched the Phagoburn clinical trial, the first international clinical study to evaluate the effectiveness of phage therapy in treating serious bacterial infections in burn victims. The randomized, controlled trial will involve 220 patients across 11 hospitals in France, Switzerland, and Belgium. If shown to be safe and effective, phage therapy could provide an alternative or supplement to antibiotics for treating antibiotic-resistant infections.
Harriet Kivumbi is a Ugandan medical doctor and public health specialist with over 15 years of experience working in HIV/AIDS, tropical diseases, and international development. She holds degrees in medicine, international health, and project management. Her experience includes clinical work, consulting for NGOs and UN agencies, and managing public health programs related to HIV/AIDS, malaria, nutrition, and emergency response. She is currently the Public Health Specialist for the ACCESS-SMC malaria prevention project in 7 Sahel countries.
New vaccines are urgently needed that can prevent both infection and disease across all populations and strains of TB, help reduce the growing problem of drug-resistant TB, and contribute to global TB elimination efforts.
The EUCLIDS project is a 5-year, 12 million Euro study funded by the European Commission to research the genetics of bacterial meningitis and sepsis in children. It involves around 5000 participants across Europe and West Africa and 14 partner institutions coordinated by Imperial College London. The project aims to determine which genes affect susceptibility to infection, severity of disease, and immune response to vaccination in order to develop better prevention and treatment strategies for bacterial diseases in children worldwide.
EVALUATION OF VACCINE ADHERENCE AND ROLE OF A CLINICAL PHARMACIST IN PAEDIAT...PARUL UNIVERSITY
Background: Immunization is one of the decisive factors in preventing various life threatening diseases. Vaccines have thrived as one of the most successful healthy intervention on that have diminished the occurrence of various infectious diseases and improved the quality of life in the population. Although the vaccine coverage has been gradually increasing, the average total immunization coverage is far less than desired outcome. Objective: The objective of our study were to enhance the quantity of vaccine delivered in the paediatric care setting, to improve Awareness of vaccination at community level by a more active involvement of clinical pharmacist on vaccination errors and missed opportunities in paediatric care setting, to analyse the extent of knowledge, attitude and practice of parents to minimize vaccination errors and avoid vaccine misconception thereby improving vaccine adherence. Results: It is a prospective observational study was conducted on 253 paediatric subjects upto 3years of age for a period of six months in a secondary care hospital, Hyderabad. The study was divided into Pre- intervention and post-intervention phases and was performed using a KAP questionnaire. The socio- demographic details were collected by using data collection form and their knowledge, Attitude and practice levels were assessed by using KAP questionnaire regarding child vaccination. Out of 253 subjects were enrolled in the study, the percentage distribution of the respondents age showed that the age group of 25-29 were predominant. The respondents with single child were observed to be more with a frequency of 132 out of 253 who received complete awareness about vaccination. Majority of the respondents were under graduates which was the main reason for lack of knowledge on immunization. Of the total 253 study population, male child were 128(50.50%) and female child were 125(49.40%). In the study, the majority of the children were neonates (103) which is 40.71%. majority of children were immunized with polio (75.49%) and least was varicella (3.55%). Of the total population, delayed or missed vaccine was 72 out of 253 i.e. 28.40% which was observed in both the genders. Missed vaccine opportunities were mostly observed for PCV, Rotavirus, and MMR. Conclusion: This study lead to optimal disease prevention through vaccination in multiple population groups while maintaining high levels of Safety and the clinical pharmacist’s interventions certainly will be helpful in providing education on immunization and improving immunization rates in the underdeveloped and developing countries. KAP questionnaire can be used in future researches on immunization and allow for better understanding of relation between mothers knowledge and immunization of children.
Similar to EVI and Hilleman Laboratories announce partnership to assess a new vaccine against Shigella (20)
The document describes a logical framework created by Hilleman Labs to evaluate potential vaccine candidates for inclusion in its research portfolio. The framework assesses candidates based on both internal factors related to Hilleman Labs' capabilities and external factors relating to public health need and market potential. It is a multi-step process intended to guide decision-making by comprehensively analyzing technical, resource, partnership and public health considerations. The goal is to select candidates that are the best strategic fit and have the highest likelihood of achieving a balanced and healthy portfolio.
Rational design of heat stable lyophilized rotavirus vaccine formulationshillemanlabs
Rotavirus (RV) is highly contagious that infects nearly every child by the age of 3–5 years and is the leading cause of diarrhea worldwide. Vaccination by rotavirus vaccines (RVVs) remains the most effective way to address the disease, consequently World Health Organization (WHO) recommends introducing RVVs worldwide to reduce the heavy burden of RV caused under-5 years diarrheal mortality.
Vaccine delivery and affordability are major bottleneckshillemanlabs
Hilleman Laboratories has entered collaborations with international organizations like Imperial College London to work on low-cost vaccine manufacturing in several developing countries. In India specifically, Hilleman has signed an agreement with NICED to further develop and commercialize Shigella vaccines and other enteric vaccines. They are also exploring a vaccine for toxic E. Coli strains. However, vaccine R&D is capital intensive and delivery challenges are a major bottleneck in India, as the delivery infrastructure is saturated. To address this, Hilleman is investigating oral vaccines and single dose options to improve delivery and affordability.
Typhoid conjugate vaccine use on adults and childrenhillemanlabs
A Phase I clinical trial of Vi-DT typhoid conjugate vaccine showed promising results. The trial was conducted in Manila, Philippines and found the vaccine to be safe and immunogenic. It induced a significant immune response in all participants. Typhoid fever remains an important public health problem, especially in developing countries, and typhoid vaccination is recommended as a control measure. New typhoid conjugate vaccines like Vi-DT are expected to provide longer lasting protection and be suitable for young children. The clinical trial of Vi-DT found it to be safe, well-tolerated and immunogenic in people aged 2-45 years. Its approval could help advance typhoid control efforts.
There is a long way to go before cholera is completely eradicated at a global level. Providing access to safe drinking water, improving basic sanitation facilities, access to basic medical care and implementing mass immunization programmed are vital components to accelerate the process of making the countries cholera-free.
Sustained funding is difficult to get in Indiahillemanlabs
Corporate India hasn’t developed a high appetite for risk, in terms of accepting new technology. India is still evolving. Most companies like to go for tried-and-tested methods, rather than innovation.
Nitya Sharma at Hilleman Labs and Amity University awarded the prestigious Pr...hillemanlabs
Nitya Sharma, a PhD scholar at Amity University, was awarded the prestigious Prime Minister’s Fellowship for her research on developing immunodiagnostic assays for meningococcal antigens at Hilleman Labs under the supervision of Dr. Manoj Kumar Chhikara. Amity University has partnered with Hilleman Labs to foster academia-industry partnerships. Nitya went through a rigorous selection process and her project was approved by the Apex Council before receiving the fellowship.
Though India has scored several successes such as eradication of polio and reduction in the rates of infant and maternal mortality, there’s a long road ahead
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by...Donc Test
TEST BANK For Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler, Verified Chapters 1 - 33, Complete Newest Version Community Health Nursing A Canadian Perspective, 5th Edition by Stamler Community Health Nursing A Canadian Perspective, 5th Edition TEST BANK by Stamler Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Study Guide Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Stuvia Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Studocu Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Test Bank For Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Pdf Download Course Hero Community Health Nursing A Canadian Perspective, 5th Edition Answers Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Ebook Download Course hero Community Health Nursing A Canadian Perspective, 5th Edition Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Studocu Community Health Nursing A Canadian Perspective, 5th Edition Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Chapters Download Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Pdf Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Study Guide Questions and Answers Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Ebook Download Stuvia Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Questions Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Studocu Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Quizlet Community Health Nursing A Canadian Perspective, 5th Edition Test Bank Stuvia
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
EVI and Hilleman Laboratories announce partnership to assess a new vaccine against Shigella
1. European Vaccine Initiative
UniversitätsKlinikum Heidelberg • Voßstr. 2, Geb. 4040 • 69115 Heidelberg • Germany
www.euvaccine.eu
EVI and Hilleman Laboratories announce partnership to assess a new
vaccine against Shigella
Funding from European and Developing Countries Clinical Trials Partnership
(EDCTP) will allow testing of a novel whole-cell inactivated oral vaccine in clinical
trials in Europe and Africa
Heidelberg and New Delhi, 7 October 2019
The European Vaccine Initiative (EVI) and Hilleman Laboratories today announced that a
multidisciplinary, international consortium coordinated by EVI has now received support from the
European and Developing Countries Clinical Trials Partnership (EDCTP) to advance a safe,
efficacious and affordable Shigella vaccine being developed by Hilleman Laboratories. The project
will be funded by EDCTP through a grant of €8.6 million.
Elaborating about the project, Dr. Stefan Jungbluth, Head of Business Development at EVI, said,
“Through this project we aim to further develop a novel oral vaccine against Shigella that we expect
will cover the commonly isolated pathogenic strains of this bacteria. This vaccine, pioneered by our
partner, Hilleman Laboratories from India, has been optimised for use in low resource settings. It
has a cost-of-goods advantage and is easy to manufacture and deliver.”
Dr. Davinder Gill, CEO, Hilleman Laboratories said, “Hilleman Labs has developed a low-cost, easy-
to-administer Shigella vaccine in collaboration with National Institute of Cholera and Enteric Disease
(NICED) Kolkata and Indian Council of Medical Research (ICMR) Institute, New Delhi, India.
Considering the huge disease burden carried by Shigella, and given that there is no licensed vaccine
currently available to address the disease, we are pleased to partner with EVI to further advance our
vaccine with funding support from EDCTP and technical support of our consortium members.
ShigOraVax will be the first-ever Indian vaccine developed to benefit people living in low and middle-
income settings. We look forward to testing safety and immunogenicity of our vaccine and to
establish clinical proof-of-concept in endemic setting”.
Shigellosis is an acute enteric infection caused by consumption of food and water contaminated with
bacteria from the genus Shigella. It is one of the leading causes of diarrhoea resulting in 165 million
cases each year, and more than 212,000 deaths in all age groups†. It is reported as the second most
common cause of diarrhoeal deaths in children under five years of age, after rotavirus. More than
50% of the Shigella burden lies in Africa. Despite its importance as a cause of major disease burden,
there is still no vaccine available for use against Shigella.
Vaccination has proven to be a key effective measure of preventing morbidity and mortality from
childhood diarrhoeal diseases, as has clearly been shown by vaccines against the rotavirus, the most
common cause of acute gastroenteritis in children. The introduction of rotavirus vaccines has been
demonstrated to be highly effective for reducing the morbidity and mortality caused by rotavirus
infections in countries that have made such vaccines part of their universal vaccination programmes.
2. 2
Other partners in the project are Leiden University Medical Center, The Netherlands, the Groupe de
Recherche Action en Santé, Burkina Faso, the Centre for Infectious Disease Research, Zambia, and
the University of Gothenburg, Sweden.
Together, through this project, the partners intend to develop the new Shigella vaccine candidate up
to mid clinical stage. Specific objectives of the project include the preparation and conduct of a Phase
Ia/Ib clinical trial in European and African adults, followed by an age de-escalating Phase II trial in
Burkina Faso, and a multi-centre phase IIb clinical trial in Burkina Faso and Zambia. Moreover,
specific epidemiologic data will be generated on the incidence of Shigella disease in the two African
countries among children under five.
Quick facts about ShigOraVax:
Start Date: 01 October 2019
End Date: 30 September 2024
Coordinator: European Vaccine Initiative (EVI)
Project Funder: EDCTP2
Total Funding: 8,6M EUR
Contacts:
Dr. Stefan Jungbluth
European Vaccine Initiative (EVI)
Email: communication@euvaccine.eu
Phone: +49 176 3161 5202
Ms. Niti Behal
MSD Wellcome Trust Hilleman Labs (P) Ltd.
Email: niti.behal@hillemanlabs.org
Phone: +91 9811944288
ShigOraVax partners:
European Vaccine Initiative (EVI) (www.euvaccine.eu), established in 1998, is a leading non-
profit organisation supporting the development of effective, accessible, and affordable vaccines for
global health. Through promoting innovative solutions for disease control involving their global
partner network of partners, EVI is striving for a world free of the intolerable burden of diseases of
poverty within the coming decades. Since its inception in 1998 EVI has contributed to the
development and clinical assessment of nearly 40 different vaccine preparations. EVI operates with
support from the European Commission, the European & Developing Countries Clinical Trials
This project is part of the EDCTP2
Programme supported by the
European Union
3. 3
Partnership (EDCTP), the Innovative Medicines Initiative (IMI), the Global Health Innovative
Technology Fund (GHIT), the Coalition for Epidemic Preparedness Innovations (CEPI) and others.
EVI is hosted by Heidelberg University in Germany.
Hilleman Laboratories (www.hillemanlabs.org) was established as an equal joint venture by MSD
and Wellcome Trust in 2009, located in New Delhi, India. Hilleman Labs is a global vaccine R & D
organization committed to developing high impact, affordable vaccines for people in developing
countries. Its translational research focuses on creating safe, affordable vaccines and delivery
solutions that are highly effective and can be easily incorporated into immunization programs.
Hilleman Lab’s focus is on transforming ideas into products and technologies through translational
R&D and by building partnerships with vaccine manufacturers. To date, its emphasis has been largely
on vaccines against infectious diseases and innovative delivery technologies for low and middle-
income countries.
Follow us on Twitter: https://twitter.com/hillemanlabs
LinkedIn: https://www.linkedin.com/company/hillemanlabs and
Facebook: https://www.facebook.com/HillemanLab/ for latest updates.
Leiden University Medical Center (www.lumc.nl) is a university medical center for research,
education and patient care with a high-quality profile and a strong scientific orientation. It has a
unique research practice, ranging from pure fundamental biomedical research to applied clinical
research. LUMC is a center for medical innovation, committed to the advancement of health care
and innovative education in line with the latest international insights and standards - and aims to play
a nationally and internationally recognized leading role in improving medicine and the quality of
health care and people’s health. The health of the global population is one of the biggest challenges
of our time. Therefore, LUMC believes in curing but also in prevention. Within the LUMC, the
Leiden Controlled Human Infection Center is a node of expertise which performs first-in-human
clinical trials to test novel vaccines as efficiently as possible and develops novel technologies to allow
for downstream clinical development in endemic areas. Its state-of-the-art facilities are exploited to
develop vaccines for the global population with a specific focus on poverty-related diseases.
Groupe de Recherche Action en Santé (GRAS) (www.gras.bf) is private research institute based
in Ouagadougou existing under the laws of Burkina Faso, operating since 2008 in the field of health
research with a focus on clinical research. The scientific staff of GRAS is multi – disciplinary with
well proven skills in clinical trials. The staff has a sound knowledge on ethical principles in research
involving human subjects and on International Conference for Harmonization – Good Clinical
Practice (ICH – GCP). Laboratory staff is certified for the shipment of dangerous goods such as bio
- specimen samples in compliance with the International Air Transportation Association (IATA)
rules. The Data management team has a strong experience with several data management software.
Thanks to its worldwide partnership GRAS has built a performant platform for Phase I to Phase IV
trials. During this last decade, scientists from GRAS have carried out more than 25 clinical trials for
various infectious diseases (Malaria vaccines, pneumococcal vaccines, Ebola vaccines, typhoid
vaccine, etc.).
Centre for Infectious Disease Research in Zambia (CIDRZ) (www.cidrz.org) is an independent
non-profit non-governmental organisation that is committed to answering key research questions
4. 4
relevant to Zambia and the region. Established in 2001, CIDRZ provides a platform for coordinated
development and deployment of state-of-the-art technologies and analyses, which can be utilized
effectively for discovery, early development, and testing of clinical products. CIDRZ aims to
improve access to quality healthcare in Zambia through innovative capacity development, exceptional
implementation science and research and impactful and sustainable public health programmes. Over
the years, the institution positioned itself as the best health research institution in Zambia through
conducting field and facility-based implementation science, and clinical trials which has enables the
organisation generate impactful evidence and frequently informs policy to improving the quality of
health care delivery in Zambia and beyond.
CIDRZ collaborates with multiple global institutions and universities. Presently, CIDRZ is
conducting 47 distinct studies and projects and is supported by a wide range of funders including,
but not limited to the European & Developing Countries Clinical Trials Partnership (EDCTP), CDC-
PEPFAR, UK-DFID, US NIH, Grand Challenge Research Fund (GCRF), Wellcome Trust, Bill &
Melinda Gates Foundation and other philanthropies.
University of Gothenburg (www.gu.se) is one of the largest universities in Scandinavia. One of its
areas of international strength is vaccines and related immunology, with world-leading expertise in
mucosal vaccines and mucosal immunology. Its achievements include e.g. (i) the development of the
first WHO-prequalified oral vaccine against cholera, and an oral vaccine against ETEC diarrhoea in
phase 2b clinical testing; (ii) the development of many of the most used immunoassays in vaccine
research (e.g. first use of ELISA in vaccinology, development of the ELISPOT method for assaying
antibody- and cytokine-secreting cells, and the intestinal lavage method for measuring intestinal
antibodies); and (iii) phase 1 to phase 4 clinical testing of vaccines in both high- and low-income
settings. The UGOT team consists of senior experts with proven world-leading experience and
expertise in oral vaccine and immunology R&D and support staff. UGOT has a wide global partner
network including organisations engaged in vaccine R&D from both public and private sector and
has long experience of participation and leadership in numerous EU- and otherwise funded vaccine
projects.
References:
† Lancet 18: 1229 (2018)